Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 10, 1986 - Issue 5
31
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Hemoglobin Sendagi (β42 Phe↠Val): A New Unstable Hemoglobin Variant Having an Amino Acid Substitution at Cd1 of the β-Chain

, , , , , & show all
Pages 469-481 | Received 19 Feb 1986, Accepted 16 Jun 1986, Published online: 07 Jul 2009
 

Abstract

Hb Sendsgi, a new unstable hemoglobin variant, was found in a Japanese male and his daughter, who have a moderate hemolytic anemia. The variant showed decreased stability upon heat and isopropanol precipitation tests. The variant did not separate from hemoglobin A by electrophoresis, but the abnormal chain emerged ahead of the normal β-chain on reverse-phase HPLC. Structural analyses revealed that the phenylalanine β42 (CD1), one of the critical amino acid residues in the heme pocket, had been replaced by valine. Oxygen equilibrium studies of the patient's hemolysates indicated that Hb Sendagi had a lowered oxygen affinity and a normal response to 2,3-diphosphoglycerate. Hb Hammersmith (β42 Phe→Ser) and Hb Louisville (Bucuresti) (β42 Phe→Leu) have previously been reported to have varying degrees of molecular instability and altered oxygen binding function. Hb Sendagi provides an additional model for elucidation of the role of the phenylalanine βCD1 on the structure and function of hemoglobin.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.